

Ulrike K Buchwald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5588236/publications.pdf>

Version: 2024-02-01

17
papers

248
citations

1162367

8
h-index

996533

15
g-index

17
all docs

17
docs citations

17
times ranked

208
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>Cryptococcus neoformans</i> infection in malignancy. <i>Mycoses</i> , 2016, 59, 542-552.	1.8	55
2	A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal conjugate vaccine in adults 50 years of age and older (PNEU-AGE). <i>Vaccine</i> , 2022, 40, 162-172.	1.7	40
3	Efficacy and effectiveness of a 23-valent polysaccharide vaccine against invasive and noninvasive pneumococcal disease and related outcomes: a review of available evidence. <i>Expert Review of Vaccines</i> , 2021, 20, 243-256.	2.0	33
4	Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, followed by sequential PPSV23 vaccination in healthy adults aged 50 years: A randomized phase III trial (PNEU-PATH). <i>Vaccine</i> , 2021, 39, 6422-6436.	1.7	25
5	Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV. <i>Aids</i> , 2022, 36, 373-382.	1.0	15
6	The importance of anal cancer screening and high-resolution anoscopy to gastroenterology practice. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 393-401.	1.0	11
7	Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature. <i>Expert Review of Vaccines</i> , 2021, 20, 257-267.	2.0	10
8	Sequential administration of Prevnar 13 and PNEUMOVAX 23 in healthy participants 50 years of age and older. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 2678-2690.	1.4	10
9	Safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, administered concomitantly with influenza vaccine in healthy adults aged 50 years: a randomized phase 3 trial (PNEU-FLU). <i>Human Vaccines and Immunotherapeutics</i> , 2021, , 1-14.	1.4	10
10	Active Tuberculosis Case Finding in Port-au-Prince, Haiti: Experiences, Results, and Implications for Tuberculosis Control Programs. <i>Tuberculosis Research and Treatment</i> , 2016, 2016, 1-11.	0.2	9
11	Immunogenicity, Safety, and Tolerability of V114, a 15-Valent Pneumococcal Conjugate Vaccine, in Immunocompetent Adults Aged 18-49 Years With or Without Risk Factors for Pneumococcal Disease: A Randomized Phase 3 Trial (PNEU-DAY). <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab605.	0.4	9
12	Anal Cancer Screening in an Urban HIV Clinic. <i>Journal of the International Association of Providers of AIDS Care</i> , 2015, 14, 497-504.	0.6	8
13	Establishing an Anal Cancer Screening Program in an Outpatient HIV Clinic: Referral Patterns and Patient Perceptions Survey. <i>Journal of the International Association of Providers of AIDS Care</i> , 2020, 19, 232595821989953.	0.6	5
14	Lot-to-lot consistency, safety, tolerability, and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in healthy adults aged 50 years: A randomized phase 3 trial (PNEU-TRUE). <i>Vaccine</i> , 2022, 40, 1342-1351.	1.7	5
15	Pelvic squamous cell cancer in an HIV-infected man with a history of high-grade anal dysplasia. <i>International Journal of Colorectal Disease</i> , 2016, 31, 1079-1080.	1.0	2
16	Response to Vyse et al., a review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK. <i>Expert Review of Vaccines</i> , 2022, , 1-2.	2.0	1
17	Further Considerations on the Natural History of Anal Dysplasia in Response to Jongen et al and Barroso. <i>Journal of Infectious Diseases</i> , 2021, 224, 1270-1271.	1.9	0